arrow
M

Mathieu Uzzan

mondor hospital
H指数:28
被引数:4,949

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of bowel urgency, disease activity and disability in patients with inflammatory bowel disease: A cross-sectional study from the GETAID

炎症性肠病患者肠道急迫感、疾病活动度与残疾的相关性:一项来自GETAID的横断面研究

2026-08-010
PRE
Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study

甲氨蝶呤治疗炎症性肠病:MICI-METHO多中心回顾性队列研究

2026-07-220
PRE
Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study

粒细胞和单核细胞吸附性单采(ADACOLUMN®)在难治性炎症性肠病患者中的真实世界经验:一项回顾性多中心队列研究

2026-07-010
PRE
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID

在溃疡性结肠炎中,继维多利珠单抗后的二线高级治疗的疗效与安全性:一项来自GETAID的多中心队列研究

2026-03-250
OAAI
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class

溃疡性结肠炎中JAK抑制剂的序贯治疗:同类别转换治疗的有效性与安全性

2025-11-030
PRE
ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 2

Yanai, H.; Feakins, R.; Allocca, M.; Burisch, J.; Ellul, P.; Iacucci, M.; Maaser, C.; Zilli, A.; Zidar, N.; Wilkens, R.; 等. ECCO-ESGAR-ESP-IBUS 关于炎症性肠病患者诊断与监测指南:第2部分. J. Crohn’s Colitis 2025, 19, jjaf106. [Google Scholar] [CrossRef]

2025-07-310
OAAI
ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1

Kucharzik, T.; Taylor, S.; Allocca, M.; Burisch, J.; Ellul, P.; Iacucci, M.; Maaser, C.; Baldin, P.; Bhatnagar, G.; Ben-Horin, S.; 等. ECCO-ESGAR-ESP-IBUS 关于炎症性肠病患者诊断与监测指南:第一部分. J. Crohn’s Colitis 2025, 19, jjaf107. [Google Scholar] [CrossRef] [PubMed]

2025-07-0120
PRE
Efficacy and safety of a second JAK inhibitor in Ulcerative Colitis: J2J multicenter cohort
2025-01-220
PRE
Effectiveness and Safety of Upadacitinib Induction Therapy in Real-World Setting for 234 Patients with Crohn's Disease: A GETAID Multicentre Cohort Study
2025-01-220
PRE
Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study
2025-01-220
PRE